Ironwood Q4/FY2021: LINZESS blockbuster >$1B; total revenue $414M; pipeline advances

IRONWOOD PHARMACEUTICALS INC

2021-FY EPS reported $3.21 revenue$413,753,000

FY2021 total revenue $414M (driven by $400M LINZESS collab revenue); GAAP net income $528M (incl $338M tax benefit).
Adjusted EBITDA $234M; year-end cash $620M.
Non-GAAP diluted EPS $1.16 vs $0.79 in FY2020; Q4 Non-GAAP EPS $0.27.
Initiated clinical studies for IW-3300 (visceral pain) and CNP-104 (primary biliary cholangitis).
LINZESS U.S. net sales exceeded $1B in 2021, achieving blockbuster status.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.